


Zenvia™ for Pseudobulbar Affect Fact Sheet

description	<p>Zenvia (formerly Neurodex) is a combination of two well-characterized compounds, the active ingredient dextromethorphan, and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. The first-in-class, dual-action glutamate inhibitor helps to regulate hyperexcitatory neurotransmission, which is implicated in pseudobulbar affect (PBA). AVANIR is developing Zenvia for use in PBA (also known as involuntary emotional expression disorder (IEED) and emotional lability) and diabetic peripheral neuropathic pain.</p>																																																		
status	<p>AVANIR has two investigational new drug applications in place for Zenvia, one for PBA and one for diabetic peripheral neuropathic pain, and has completed three Phase I clinical trials to evaluate the safety and pharmacokinetics of the drug combination of dextromethorphan and the enzyme inhibitor. Two controlled, multicenter Phase III clinical trials have been conducted evaluating the use of Zenvia in the treatment of PBA; one in ALS patients with PBA, and the other in MS patients with PBA. In October 2006, the Company received an approvable letter for the treatment of Zenvia in PBA. To address safety concerns raised in the FDA's approvable letter for Zenvia for the treatment of PBA, the company intends to initiate a confirmatory Phase III study with a new lower quinidine dose formulation of Zenvia. In April 2007 AVANIR completed a Phase III study in patients with diabetic peripheral neuropathic pain where all primary endpoints were successfully met.</p>																																																		
indication	<p>Pseudobulbar affect (PBA) is characterized by sudden and unpredictable episodes of crying, laughing, or other emotional displays. PBA can occur when disease or injury damages the area of the brain that controls normal expression of emotion. This damage can disrupt brain signaling, causing a "short circuit", triggering episodes of involuntary emotional expressions. PBA is often misdiagnosed as depression. Contrary to depression, PBA episodes are often sudden, unpredictable, and contrary to the person's mood. For some, these episodes can be so disruptive that they avoid social situations, which can result in isolation. It is hypothesized that neurological disease or brain injury may lead to excessive signaling of the excitatory neurotransmitter, glutamate, which can manifest as PBA episodes.</p>																																																		
company product pipeline	<p>AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.</p> <p>AVANIR's products and product candidates address therapeutic markets that include the central nervous system, inflammation and infectious disease.</p> <div data-bbox="412 1394 1393 1919" style="border: 1px solid black; padding: 10px;"> <p>2007 PRODUCT PIPELINE </p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2"></th> <th colspan="2">RESEARCH ^(a)</th> <th colspan="3">CLINICAL ACTIVITIES ^(a)</th> <th rowspan="2">Regulatory Approval</th> </tr> <tr> <th>Preclinical</th> <th></th> <th>Phase I</th> <th>Phase II</th> <th>Phase III</th> </tr> </thead> <tbody> <tr> <td rowspan="2">CNS</td> <td colspan="6">Zenvia™ (Pseudobulbar Affect) ^(b)</td> </tr> <tr> <td colspan="6">Zenvia (Diabetic Peripheral Neuropathic Pain)</td> </tr> <tr> <td rowspan="4">Non-CNS</td> <td colspan="6">Abreva® (HSV1) ^(c) <i>GlaxoSmithKline</i></td> </tr> <tr> <td colspan="6">Selective Cytokine Inhibitor ^(d)</td> </tr> <tr> <td colspan="6">MIF Inhibitor ^(e) Novartis</td> </tr> <tr> <td colspan="6">Xenerex™ (HuMAb Platform)</td> </tr> </tbody> </table> <p style="font-size: small;"> ^{a)} Timelines in the pictorial representations are not to scale. ^{b)} The NDA for Zenvia is currently filed and the Company intends to conduct a confirmatory Phase III study in PBA at the request of the FDA. ^{c)} Granted to GlaxoSmithKline exclusive rights to market docosanol 10% cream in North America. ^{d)} Effective November 9, 2006, we placed on hold activities associated with the selective cytokine inhibitor. ^{e)} Novartis has assumed all continuing research and development activities. </p> </div>		RESEARCH ^(a)		CLINICAL ACTIVITIES ^(a)			Regulatory Approval	Preclinical		Phase I	Phase II	Phase III	CNS	Zenvia™ (Pseudobulbar Affect) ^(b)						Zenvia (Diabetic Peripheral Neuropathic Pain)						Non-CNS	Abreva® (HSV1) ^(c) <i>GlaxoSmithKline</i>						Selective Cytokine Inhibitor ^(d)						MIF Inhibitor ^(e) Novartis						Xenerex™ (HuMAb Platform)					
	RESEARCH ^(a)		CLINICAL ACTIVITIES ^(a)			Regulatory Approval																																													
	Preclinical		Phase I	Phase II	Phase III																																														
CNS	Zenvia™ (Pseudobulbar Affect) ^(b)																																																		
	Zenvia (Diabetic Peripheral Neuropathic Pain)																																																		
Non-CNS	Abreva® (HSV1) ^(c) <i>GlaxoSmithKline</i>																																																		
	Selective Cytokine Inhibitor ^(d)																																																		
	MIF Inhibitor ^(e) Novartis																																																		
	Xenerex™ (HuMAb Platform)																																																		